Myelodysplastic syndromes are characterized by leukemic progression in about a third of cases and the progression is a major cause of death. Evolution constitutes a major problem and the outcome is highly variable, especially in the low-and intermediate-risk categories, even though established with the refined International Prognostic Scoring System (IPSS), capable of a better predictivity with respect to the French-American-British (FAB) classification. In these cases, mostly normal or low-risk karyotypic changes are found. 1 The high-risk group often shows progression to acute myeloid leukemia (AML), being unresponsive to chemotherapy and AML is the cause of death, even though a number of patients do not progress to AML or are highly responsive to the treatment. The karyotype, carried out by GTG banding at diagnosis, could be normal, but cryptic rearrangements and deletion could change the risk status in some of the patients. 2 The analysis we previously reported 3 is based on a small number of patients (nine), with normal GTG banding karyotype and, as characterized by different meaning, that is FAB or IPSS, belonging to high-risk group. The patients' age was ranging from 58 to 77 years, and for different reasons, they were supplied only with supportive treatment. Four patients showed the monoallelic deletion of inositide-specific phospholipase C b1 (PI-PLCb1), whereas five did not. The latter patients at the time of the publication of the report were still alive, ranging the survival after diagnosis from 30 to 32 months. The four patients affected by the deletion died within 1-6 months after diagnosis from AML evolution.
Indeed, our data are strictly related to high-risk patients, as evaluated by clinical meanings, that is, FAB and IPSS, but bearing a normal karyotype, that from a cytogenetic point of view only, could be considered with favorable prognosis. We are keen to stress this point, even though in the Lo Vasco et al. paper, 3 the clinical features have not been fully explained. Even though the number of cases is small, we reckon that in this peculiar type of patients, the cryptic deletion of PI-PLCb1 gene is not a rare event. Therefore, in order to address this point as well as to further the understanding of the relationship between PI-PCLCb1 gene deletion and MDS/AML progression, we are currently evaluating a larger number of patients, coming from the Haematology Department of the University of Bologna, all with normal karyotype both at diagnosis and during disease progression, belonging to high risk, 13 patients (mean age 65 years), and low/intermediate risk, 10 patients (mean age 73 years), as established by IPSS and FAB as well. The rationale is based on the fact that the data reported by Lo Vasco et al.
3 might be of importance to identify a high-grade MDS/AML population, with a common pathophysiology owing to altered function of a key signalling intermediate in the control of cell cycle progression, that is, PI-PCLCb1. This also implies that the Lo Vasco et al. paper 3 is not aimed at all to change or challenge the value of the clinical parameters used for MDS classification, but is only aimed to give more insight into the intriguing and complex issue of MDS.
The FISH analysis carried out using the PI-PCLCb1 probe (PAC clone HS881E24 from P de Jong RPCI-5 PAC library) confirms that low-risk patients do not bear the deletion of PI-PCLCb1 gene and did not evolve to AML even in the absence of supportive care. On the contrary, four high-risk patients bear the deletion of PI-PCLCb1 gene, are unresponsive to MDS treatment and evolved to AML. The remaining nine high-risk patients do not show the deletion of PI-PCLCb1 gene and are responsive to MDS treatment.
Therefore, we reckon that a key point is the disclosure of specific classes of patients and that the identification of a highgrade MDS/AML population in patients bearing a normal GTG karyotype could be of importance in furthering the pathophysiology of MDS and of support for prognosis. In addition, this is also an answer to the Correspondence that appeared recently in Leukemia. 4 To achieve this goal, we are extending the analysis on this type of patients by collaborating with British centers in order to accumulate as much data as possible, but we do also ask other groups to enter the fray. In addition, in replying to Herens et al., 5 we add that we are keen to share our samples for further analysis. Moreover, it should be interesting to know also in the group of patients examined by Herens et al. how many of them belong to the high-risk group.
In conclusion, we do believe that a better and more comprehensive understanding of the alterations of signalling pathways in high-grade MDS/AML is necessary, given that these metabolic events are fundamental for the control of cell cycle progression. Interestingly, it has been very recently shown that frequent elevation of Akt kinase phosphorylation in bone marrow and peripheral blood mononuclear cells from high-risk MDS patients takes place, 6 and this could be related to an increase of phosphatidylinositol-bisphosphate, the substrate of both PI-PCLCb1 and of phosphatidylinositol 3-kinase, the enzyme that phosphorylates the Akt Kinase.
7 From a biological point of view, it could be that the increased availability of phosphatidylinositol-bisphosphate, owing to the monoallelic deletion of PI-PCLCb1 gene and partial loss of function of the PI-PCLCb1 itself in high-risk MDS patients, could pave the way for the well-known antiapoptotic pathway elicited by the phosphatidylinositol 3-kinase/Akt Kinase cascade, which in turn could increase the survival of MDS blasts in the bone marrow. In their letter, 1 commenting to our paper, 2 Lo Vasco et al. precise the prognostic data of the MDS patients included in their original paper 3 on cryptic deletions of the inositide-specific phospholipase c b1 gene (PI-PLC b1). All the patients with MDS and a normal karyotype at diagnosis were at high risk as evaluated by clinical meanings (French-American-British classification (FAB), International Prognostic Scoring System (IPSS)). In our series, 2 selection of the patients was done according to the unique criteria given by Lo Vasco et al. in their original paper, 3 that is, the evidence of a normal karyotype at diagnosis. The IPSS score in our cases was low (12 patients), intermediate (10) or high (1) . The discrepancies between the results of both studies probably can be explained by differences in the selection of the MDS populations. The data of Lo Vasco, 1,3 strictly related to high-risk IPSS categories, show that, respectively, 4/9 and 4/13 cases bear the PI-PLC b1 deletion. On the contrary, in our series where only one patient was at high risk, none of the 23 patients showed a cryptic deletion of band 20p12.3.
2 Similar observations were recently done by Verburgh et al. 4 who failed to detect a deletion of the PI-PLC b1 gene in a series of 33 MDS patients with normal karyotype, of which two belonged to the high-risk group as defined by the IPSS. In the same way, no deletion was observed in the 10 low-risk MDS patients reported in the comment of Lo Vasco et al. 1 All these data indicate that the deletion of the PI-PLC b1 gene probably will not be detected in MDS patients with normal karyotype and low or intermediate IPSS risks. Conversely, in the high-risk group, the deletion could be frequent (about one-third of the reported cases till now) and associated with alterations of the signalling pathways and short survivals. 
